Clinical Overview

Epithelial ovarian cancer (EOC) represents one of the most promising applications for ctDNA-based minimal residual disease (MRD) monitoring, with recent prospective studies demonstrating powerful prognostic stratification and exceptional lead times for recurrence detection. Despite the anatomical challenges of peritoneal dissemination, tumor-informed ctDNA testing achieves 93-100% baseline sensitivity and provides a median lead time of 5.9-10 months before radiographic recurrence, among the longest of any solid tumor.

The 2024-2025 data from multiple independent cohorts has established MRD-positive status after primary treatment as one of the strongest predictors of early recurrence, with hazard ratios of approximately 5-7 for progression-free survival. These findings position ctDNA surveillance as a complementary tool to CA-125 monitoring, offering superior specificity and earlier detection than traditional serum markers.

Key Clinical Applications:

Post-Surgical MRD Detection: 93-100% baseline detection rate; HR ~5-7 for recurrence risk
Early Recurrence Detection: Median lead time 5.9-10 months before imaging (CT/MRI)
Complementary to CA-125: 100% sensitivity and specificity in post-surgical relapse detection
Treatment Response Monitoring: Real-time assessment of therapy effectiveness
Longitudinal Surveillance: Serial monitoring during follow-up identifies molecular relapse

Emerging Evidence (2024-2025): Multiple prospective studies now demonstrate that ctDNA MRD detection after primary therapy powerfully predicts progression-free survival. MRD-positive patients at end of treatment have 5-7 times higher risk of progression, with ctDNA positivity preceding radiographic recurrence by an average of 5.9-10 months. This extended lead time creates a critical window for potential therapeutic intervention.

ctDNA Testing Methodology

ctDNA Detection Performance in Ovarian Cancer

Detection Performance:

Baseline Detection: 93-100% sensitivity at diagnosis
MRD Sensitivity: Post-surgically detects relapse with 100% sensitivity and specificity in prospective studies
Detection Threshold: Highly sensitive detection down to 0.001-0.01% variant allele frequency
Surveillance: Serial blood draws at defined intervals (typically every 3 months) enable longitudinal MRD monitoring

Clinical Consideration: Ovarian cancer ctDNA testing achieves high sensitivity for MRD detection, with the ability to detect minimal residual disease in the post-surgical setting and enable early detection of molecular relapse during surveillance.

LIQOMICS Testing Solutions for Ovarian Cancer

CancerVista offers tumor-informed ctDNA testing for Ovarian Cancer enabling MRD detection after debulking surgery and therapy response monitoring.

Key Features:

Baseline profiling from tissue biopsy or plasma sample
Ultra-high sensitivity for MRD detection
Tracks patient-specific mutations for specific and precise MRD quantification
Enables ctDNA-guided therapy decisions
Allows early relapse detection during surveillance

Learn More About CancerVista →

MRD Detection: Prognostic Significance

Post-Treatment ctDNA as Predictor of Recurrence

Detection of ctDNA after completion of primary therapy (surgery ± chemotherapy) identifies patients at markedly elevated risk of disease recurrence. Multiple 2024-2025 prospective studies have established post-treatment ctDNA status as one of the most powerful prognostic factors in ovarian cancer.

Clinical Cancer Research 2025 Study (95 Patients)

A prospective study of 95 ovarian cancer patients evaluated both surgical MRD (second-look laparoscopy, SLL) and ctDNA testing to assess prognostic value.

Key Findings:

ctDNA Positivity Rate: 34% (15/44) of patients with available ctDNA testing were MRD-positive
Progression-Free Survival:
- ctDNA-positive: 6.4 months median PFS
- ctDNA-negative: 28.1 months median PFS
- P < 0.001
Overall Survival:
- ctDNA-positive: 32.4 months median OS
- ctDNA-negative: Not reached
- P = 0.008
Surgical MRD (SLL): Also prognostic with HR 4.40 for OS (95% CI 1.37-14.21, p=0.013)

Gynecologic Oncology 2024/2025 Study (31 Patients)

Landmark analysis of MRD status in 31 ovarian cancer patients using tumor-informed ctDNA testing.

Prognostic Performance:

Hazard Ratio: HR 6.678 for PFS (MRD+ vs MRD-, p = 0.01)
Median PFS:
- MRD-positive: 5.8 months
- MRD-negative: 24.7 months
Clinical Interpretation: MRD-positive patients have nearly 7-fold higher risk of progression
Conclusion: MRD detection via ctDNA establishes as valuable tool for early and accurate prediction of ovarian cancer recurrence

ASCO 2024 Abstract (Chen K et al.)

Post-Treatment ctDNA Prognostic Value:

Study: Evaluation of ctDNA-based MRD in ovarian cancer adjuvant therapy (J Clin Oncol 2024;42(suppl 16):5525)
Key finding: ctDNA-based MRD provided real-time assessment of postoperative adjuvant therapy efficacy and predicted recurrence

Systematic Review and Meta-Analysis (2026)

Pooled ctDNA MRD Evidence (Crit Rev Oncol Hematol 2026):

Scope: Systematic review and meta-analysis of ctDNA for MRD detection in ovarian cancer
Key Finding: ctDNA positivity associated with significantly increased recurrence risk and inferior survival outcomes across pooled data
Conclusion: ctDNA is a validated novel prognostic tool for MRD detection in ovarian cancer with consistent performance across heterogeneous study populations

Prospective Recurrent EOC Study (2024)

Recurrent Epithelial Ovarian Cancer (27 patients):

Positive Predictive Value: 100% for recurrence
Negative Predictive Value: 96.7%
Conclusion: ctDNA is a potential biomarker for MRD monitoring with near-perfect predictive accuracy in recurrent EOC

Consistent Prognostic Impact Across Studies

The consistency of hazard ratios across independent cohorts, now confirmed by meta-analysis, establishes ctDNA MRD detection as a robust prognostic biomarker in ovarian cancer. MRD-positive patients consistently demonstrate substantially higher risk of progression with median PFS of 5.8-6.4 months versus 24.7-28.1 months for MRD-negative patients. A 2026 systematic review confirmed that ctDNA positivity is associated with increased recurrence risk and inferior survival outcomes across heterogeneous study populations.

Lead Time for Recurrence Detection

ctDNA Detects Relapse Months Before Imaging

One of the most clinically significant advantages of ctDNA monitoring in ovarian cancer is the extended lead time between molecular detection and radiographic recurrence. This window of opportunity is among the longest reported in solid tumors.

Lead Time Data from Prospective Studies:

Median Lead Time (Study 1): 5.9 months (range: not specified)
- 12 patients: ctDNA detected progression earlier than standard surveillance
Median Lead Time (Study 2): 10 months average
- ctDNA preceded radiological findings by average of 10 months
- 100% sensitivity and specificity for relapse detection
Lead Time Range (Study 3): 14-1,417 days (median 179 days = ~6 months)
- 12 patients (55%): positive ctDNA sample preceded progression

Clinical Performance: Detection Sensitivity

Baseline and Relapse Detection Rates:

Baseline Detection: 93% (51/55 samples at diagnosis) to 100% in various studies
Progression Detection: 100% (18/18 samples at progression)
Post-Surgical Relapse: 100% sensitivity and specificity for detecting recurrence
Overall Performance: Highly predictive marker with significantly improved detection lead time compared to conventional monitoring

Clinical Implication of Extended Lead Time

The 5.9-10 month lead time in ovarian cancer represents one of the longest intervals between molecular and radiographic detection across all solid tumors. This extended window creates opportunities for clinical trial enrollment, re-challenge with platinum therapy in appropriate candidates, or initiation of novel therapies before symptomatic progression. Active trials are evaluating whether intervention at the time of molecular relapse improves outcomes compared to waiting for imaging-detected recurrence.

Clinical Utility: Serial Monitoring Strategy

Recommended Surveillance Approach

Based on the prospective study data, ctDNA monitoring provides value at multiple timepoints in the ovarian cancer treatment continuum.

Suggested Clinical Workflow

Timepoint	ctDNA Application	Clinical Significance
Baseline (Diagnosis)	Initial tumor profiling from tissue or blood	93-100% detection rate; establishes patient-specific mutations for tracking
Post-Surgery (4-8 weeks)	MRD assessment	Identifies residual disease; HR ~5-7 for progression risk
End of Chemotherapy	Treatment response assessment	MRD+ patients: median PFS 5.8-6.4 months vs 24.7-28.1 months if MRD-
Surveillance (Every 3 months)	Serial monitoring for molecular relapse	Median 5.9-10 month lead time before imaging recurrence
At Clinical Suspicion	Confirmation of relapse	100% sensitivity for progression detection

Complementary Use with CA-125

ctDNA monitoring complements traditional CA-125 surveillance:

CA-125 Limitations: ~20% of ovarian cancers do not secrete CA-125; false positives from benign conditions
ctDNA Advantages: Tumor-specific mutations eliminate false positives; detects relapse in CA-125-negative cases
Combined Approach: Serial CA-125 + ctDNA monitoring may optimize early recurrence detection
Specificity: ctDNA provides superior specificity compared to CA-125 elevation alone

Active Clinical Trials

Interventional Studies in Ovarian Cancer

NCT05212779: Predicting Recurrence Using ctDNA

Study Question: Can ctDNA detect recurrent ovarian cancer earlier than radiographic imaging (RECIST 1.1)?
Design: Prospective trial assessing lead time advantage of ctDNA vs CT/MRI
Clinical Impact: Will establish whether earlier detection via ctDNA enables improved outcomes with timely intervention
Status: Actively enrolling patients

Future Directions: Randomized trials testing ctDNA-guided therapy intensification (similar to DYNAMIC in colorectal cancer or IMvigor011 in bladder cancer) are needed to determine whether acting on MRD-positive status improves progression-free or overall survival in ovarian cancer. The DYNAMIC-Ovarian trial is prospectively evaluating ctDNA as a dynamic prognostic marker at multiple timepoints during neoadjuvant and adjuvant settings.

Genotyping: BRCA Reversion Mutations and PARP Inhibitor Monitoring

ctDNA for Treatment Resistance Detection

Beyond MRD monitoring, ctDNA-based molecular profiling plays an increasingly important role in detecting resistance mechanisms to PARP inhibitor and platinum-based therapy in ovarian cancer, particularly in BRCA-mutant tumors.

BRCA Reversion Mutations

Clinical Significance:

Mechanism: Secondary BRCA mutations that restore protein function, conferring resistance to both platinum chemotherapy and PARP inhibitors
Detection: Targeted next-generation sequencing of circulating cell-free DNA enables non-invasive detection of reversion mutations
Clinical Impact: Detection of BRCA reversion mutations in ctDNA predicts resistance to subsequent PARP inhibitor therapy and may guide switch to alternative treatments
Prevalence: Detected in approximately 20-45% of BRCA-mutant ovarian cancers at time of PARP inhibitor resistance

TP53 Mutation Monitoring for Treatment Response

TP53 ctDNA as Response Biomarker:

Prevalence: TP53 mutations present in >95% of high-grade serous ovarian cancers
ARIEL2 Study: Reduction in TP53 mutation frequency in ctDNA during rucaparib treatment was associated with response to therapy
Dynamic Monitoring: Serial TP53 ctDNA levels reflect treatment response more dynamically than CA-125, with shorter half-life (cleared within 1 week post-debulking surgery)
Clinical Application: TP53 variant allele frequency tracking in plasma enables real-time assessment of treatment efficacy during chemotherapy and PARP inhibitor maintenance

Comprehensive Genomic Profiling via ctDNA

Blood-based comprehensive genomic profiling enables detection of multiple actionable alterations including BRCA1/2, BRCA reversion mutations, TP53, ARID1A, CCNE1, KRAS, MYC, PIK3CA, and PTEN, supporting treatment selection without requiring repeat invasive tissue biopsy.

Emerging Application: PARP Inhibitor Guidance: ctDNA monitoring offers potential to guide clinician decision-making regarding continuation or discontinuation of PARP inhibitor maintenance therapy in patients with recurrent epithelial ovarian cancer. Rising ctDNA levels during PARP inhibitor therapy may indicate emerging resistance and prompt consideration of alternative treatment strategies, while ctDNA clearance supports continued maintenance.

Key Takeaways for Clinicians

                    Evidence Summary: Ovarian Cancer ctDNA MRD
                    Strong Prognostic Value: HR ~5-7 for PFS consistently across multiple 2024-2025 cohorts
Exceptional Lead Time: 5.9-10 month median lead time before imaging, among the longest in solid tumors
High Sensitivity: 93-100% baseline detection; 100% sensitivity and specificity for relapse
Tumor-Informed Approach: Requires baseline tissue or plasma for patient-specific mutation tracking
Clinical Workflow: Serial monitoring every 3 months during surveillance phase
Complementary to CA-125: Adds specificity and detects CA-125-negative relapses
Genotyping Utility: BRCA reversion mutation detection guides PARP inhibitor decisions; TP53 ctDNA tracking provides dynamic response monitoring
PARP Inhibitor Monitoring: ctDNA may guide continuation/discontinuation of maintenance therapy
Meta-Analysis Confirmed: 2026 systematic review validated ctDNA as prognostic tool for MRD across heterogeneous populations
Emerging Evidence: 2024-2026 data rapidly expanding; DYNAMIC-Ovarian and other interventional trials underway

                

Clinical Bottom Line: ctDNA MRD testing in ovarian cancer provides powerful prognostic stratification with exceptional lead time for recurrence detection. While interventional trials are still needed to prove survival benefit, the consistency of HR 5-7 across independent cohorts and the 5-10 month detection advantage position ctDNA as a valuable surveillance tool complementary to CA-125 and imaging.

References

Knisely AT, et al. Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities. Clin Cancer Res. 2025;31(19):4122-4135.
Shu T, et al. The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer. Gynecol Oncol. 2025;192:94-101.
Chen K, Guo Y, et al. Value of ctDNA-based molecular residual disease (MRD) in evaluating the adjuvant therapy effect in ovarian cancer. J Clin Oncol. 2024;42(suppl 16):5525. Presented at ASCO 2024 Annual Meeting.
Kallio HML, Savolainen K, et al. Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer. Life Sci Alliance. 2024;7(6):e202402658.
Hou JY, et al. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecol Oncol. 2022;167(2):334-341.
ClinicalTrials.gov NCT05212779: Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease.
Tian X et al. Prognostic value of circulating tumor DNA for minimal residual disease detection in ovarian cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2026 (in press).
Christie EL et al. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol 2017;35:1274-1280.
Swisher EM et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18:75-87.
Parkinson CA et al. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Cancer 2024;130:e11663307.

Ovarian Cancer